PharmaNetics’s products and technologies were acquired by Helena Laboratories last year and have since been moved to Beaumont. The new products expanded Helena’s Point of Care division, which includes products for blood platelet function screening and activated clotting time-testing.
Before being acquired, PharmaNetics stated that it will distribute the cash received from selling its assets to shareholders within one year of closing the final sale. It can be speculated that the issue will be addressed soon.
Please share your thoughts: